GlassScriptPhysician profile
Florence Nappi
NPI 1306265939
$9,434.32
in general payments reported to CMS, 2019-2025
35 companies · $2,001 in 2025
The $2,001 reported for 2025 was more than what 76% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,063 · 2020: $680 · 2021: $1,101 · 2022: $1,160 · 2023: $1,429 · 2024: $2,001 · 2025: $2,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,281 · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,281.47 |
| Education | $149.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,077.47 | 2019-2025 | |
| Janssen Biotech, INC. | $1,173.92 | 2019-2025 | Tremfya, Stelara, Simponi |
| Genzyme Corporation | $854.10 | 2019-2025 | |
| Leo Pharma INC. | $853.52 | 2019-2025 | Adbry |
| Lilly USA, LLC | $569.94 | 2020-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $547.77 | 2019-2025 | |
| Galderma Laboratories, L.P. | $512.54 | 2019-2025 | Nemluvio |
| Pfizer INC. | $411.26 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $331.64 | 2019-2025 | Ilumya, Odomzo |
| E.R. Squibb & Sons, L.L.C. | $254.35 | 2023-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $242.47 | 2019-2025 | Libtayo, Dupixent |
| Dermavant Sciences, INC. | $206.97 | 2023-2024 | Vtama |
| Mayne Pharma Commercial LLC | $200.08 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $165.07 | 2023-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.78 | 2024-2025 | Spevigo |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $99.80 | 2019-2025 | Cabtreo |
| Janssen Scientific Affairs, LLC | $94.05 | 2019 | |
| Ucb, INC. | $83.39 | 2019-2025 | Bimzelx |
| Biofrontera INC. | $83.04 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Organon LLC | $78.89 | 2025 | Vtama |
| Genentech USA, INC. | $52.54 | 2020-2021 | |
| Verrica Pharmaceuticals INC. | $45.12 | 2024 | Ycanth |
| Dermira, INC. | $44.81 | 2019 | |
| Amgen INC. | $44.73 | 2023 | Otezla |
| Vyne Pharmaceuticals INC. | $39.11 | 2020-2021 | |
| Dusa Pharmaceuticals, INC. | $35.98 | 2019 | |
| Blueprint Medicines Corporation | $26.29 | 2024 | Ayvakit |
| Sanofi-Aventis U.S. LLC | $24.96 | 2019 | |
| Journey Medical Corporation | $24.69 | 2021 | |
| Organogenesis INC. | $24.67 | 2023 | Puraply |
| Aclaris Therapeutics, INC. | $24.34 | 2019 | |
| Paratek Pharmaceuticals, INC. | $21.16 | 2020 | |
| Tempus Ai, INC | $20.75 | 2024 | Merlin Test |
| Incyte Corporation | $19.08 | 2024 | Opzelura |
| Merck Sharp & Dohme LLC | $12.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Florence Nappi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.